首页> 外文会议>Protein Engineering Summit. >HERA-GITRL: A Novel Hexavalent Human GITR Agonist Promoting AntiCancer Immunity by Enhancing T Cell Activation
【24h】

HERA-GITRL: A Novel Hexavalent Human GITR Agonist Promoting AntiCancer Immunity by Enhancing T Cell Activation

机译:Hera-GITR1:一种通过提高T细胞活化来促进抗癌免疫的新型六价人聚乙烯激动剂

获取原文

摘要

Members of the tumor necrosis factor receptor superfamily (TNFR-SF) are key factors in human immune regulation. Apogenix has developed a proprietary technology platform to produce novel hexavalent TNFR-SF agonists (HERA) suitable for immune-oncological (IO) therapies. The HERA fusion proteins are based on trivalent, single-chain, molecular mimics of the TNF-SF receptor binding domains (scTNF-SF-RBDs) fused to a silenced human IgGl-Fc-domain serving exclusively as a dimerization scaffold. Hence, one HERA molecule is capable of clustering six receptor chains in a spatially well-defined manner and thereby inducing potent agonistic activity. In contrast to bivalent antibodies, HERA ligands convey their agonistic effects without secondary crosslinking. In addition, the short half-life of HERA proteins, relative to antibodies, facilitates the fast-in/fast-out dynamics essential for IO-combination therapies and avoidance of immune system overstimulation. The HERA concept has been successfully translated to HERA-TRAIL (now in Phase I), -GITRL, -CD40L, -OX40L, -4-1BBL, -LIGHT and -CD27L. Here we report in vitro and in vivo properties of our novel HERA-GITRL constructs. HERA-GITRL proteins were expressed in CHO-S cells and purified by a two-column-based lab-scale chromatographic process resulting in pure protein lots without aggregates/high molecular weight species. Pharmacokinetic (PK) parameters were determined using CD1-mice and cynomolgus monkeys, a relevant species. For functional in vitro characterization of HERA-GITRL, human immune cells isolated from healthy-donor blood were profiled by multicolor flow cytometry for changes in activation marker expression, proliferation rate and cytokine production. The signaling efficacy of HERA-GITRL was assessed by a reporter gene assay. For in vivo experiments, a murine surrogate, mmHERA-GITRL, was created and used for the evaluation of anti-tumor effects.
机译:肿瘤坏死因子受体超家族(TNFR-SF)的成员是人免疫调节的关键因素。 Apogenix开发了一种专有技术平台,用于生产适合免疫肿瘤疗法的新型六价TNFR-SF激动剂(HERA)。 Hera融合蛋白基于TNF-SF受体结合结构域(SCTNF-SF-RBD)的三价,单链分子模拟物,其与沉默的人IgG1-Fc-结构域仅作为二聚化支架融合。因此,一个HERA分子能够以空间明确定义的方式聚集六个受体链,从而诱导有效的激动活性。与二价抗体相反,Hera配体在没有二次交联的情况下传达它们的激动作用。此外,相对于抗体的Hera蛋白的短暂半衰期促进了对IO组合疗法的快速/快速动态,避免了免疫系统过度刺激。 Hera Concept已成功转换为Hera-trail(现在在IPSE I),-GITRL,-CD40L,-OX40L,-4-1BBL,-Light和-CD27L。在这里,我们在微粒中报告我们的新型英雄-GIT1构建体的体内性质。 Hera-GITR1蛋白质在CHO-S细胞中表达,并通过基于双柱的实验室测量的色谱法纯化,得到纯蛋白质批量而没有聚集/高分子量物种。药代动力学(PK)参数使用CD1-小鼠和Cynomolgus猴,一种相关物种测定。对于Hera-GITR1的功能性体外表征,通过多色流式细胞术分离出从健康供体血液中分离的人免疫细胞进行激活标记表达,增殖率和细胞因子产生的变化。通过报告基因测定评估Hera-GITR1的信号传导效果。对于体内实验,产生鼠替代物Mmhera-GITR1并用于评估抗肿瘤效应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号